Cargando…
A Drug Combination Rescues Frataxin-Dependent Neural and Cardiac Pathophysiology in FA Models
Friedreich’s ataxia (FA) is an inherited multisystemic neuro- and cardio-degenerative disorder. Seventy-four clinical trials are listed for FA (including past and present), but none are considered FDA/EMA-approved therapy. To date, FA therapeutic strategies have focused along two main lines using a...
Autores principales: | Abeti, Rosella, Jasoliya, Mittal, Al-Mahdawi, Sahar, Pook, Mark, Gonzalez-Robles, Cristina, Hui, Chun Kiu, Cortopassi, Gino, Giunti, Paola |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9160322/ https://www.ncbi.nlm.nih.gov/pubmed/35664670 http://dx.doi.org/10.3389/fmolb.2022.830650 |
Ejemplares similares
-
Erratum: A Drug Combination Rescues Frataxin-Dependent Neural and Cardiac Pathophysiology in FA Models
Publicado: (2022) -
Dyclonine rescues frataxin deficiency in animal models and buccal cells of patients with Friedreich's ataxia
por: Sahdeo, Sunil, et al.
Publicado: (2014) -
Dimethyl fumarate dosing in humans increases frataxin expression: A potential therapy for Friedreich’s Ataxia
por: Jasoliya, Mittal, et al.
Publicado: (2019) -
Metal Ion Binding in Wild-Type and Mutated Frataxin: A Stability Study
por: Morante, S., et al.
Publicado: (2022) -
Frataxin Deficiency Promotes Excess Microglial DNA Damage and Inflammation that Is Rescued by PJ34
por: Shen, Yan, et al.
Publicado: (2016)